Malaria depends on number of parasites, not bites: study

Only registered malaria vaccine, RTS,S, has had only partial efficacy in recent trials

Zydus ties up with Medicines for Malaria Venture to co-develop antimalarial drug
Press Trust of India London
Last Updated : Jan 13 2017 | 3:37 PM IST
For the first time, scientists have found that the number of parasites each mosquito carries, rather than the number of bites, determines the chance of successful malaria infection, an advance that may help develop effective vaccines for the deadly infection.

The findings, from scientists at Imperial College London, may also explain why the only registered malaria vaccine, RTS,S, has had only partial efficacy in recent trials.

Malaria is spread when mosquitoes bite humans and release microscopic parasites, which live in the salivary glands of the mosquitoes, into the person's bloodstream.

The parasites then travel to the liver, where they mature and multiply for 8-30 days before spreading throughout the bloodstream and causing the symptoms of malaria.

To determine the intensity of malaria transmission, researchers and international organisations like the World Health Organisation currently rely on a measure called the entomological inoculation rate (EIR): the average number of potentially infectious mosquito bites per person per year.

However, this does not take into account how infectious each of those bites may be - each bite is considered equally infectious.

Now, researchers have determined that the number of parasites each individual mosquito carries influences whether a person will develop malaria.

Some mosquitoes can be 'hyperinfected', making them particularly likely to pass on the disease.

In studies in mice, the researchers determined that the more parasites present in a mosquito's salivary glands, the more likely it was to be infectious, and also the faster any infection would develop.

"These findings could have significant implications for public health. We have shown that the concept of relying on the number of bites alone to predict malarial burden is flawed, and has probably hampered the successful use of control measures and the development of effective vaccines," said Andrew Blagborough, from the Department of Life Sciences at Imperial.

"It is surprising that the relationship between parasite density and infectiousness has not been properly investigated before, but the studies are quite complex to carry out," said Blagborough.

By conducting further studies with mice and human volunteers, the team was also able to explain why the malaria vaccine RTS,S is effective only around 50 per cent of the time, and why any protection rapidly drops off after three years.

"Vaccine development has come a long way, and this new insight should help future vaccine studies to be tested more rigorously," said Thomas Churcher, from the MRC Centre for Outbreak Analysis and Modelling at Imperial.

The study was published in the journal PLoS Pathogens.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 13 2017 | 3:02 PM IST

Next Story